CorMedix Therapeutics will announce its financial results for the first quarter ending March 31, 2026, before market open on May 14, 2026. The company will also host a corporate update conference call at 8:30 AM Eastern Time on the same day. CorMedix focuses on developing and marketing therapeutic products for serious diseases in the U.S., particularly in institutional healthcare settings. This update follows recent positive clinical trial results, highlighting the company's ongoing progress.
Copart's stock is under pressure following a Barclays analyst downgrade to a $26 price target and significant insider selling by a company director. The company faces a securities fraud investigation after CEO Jeff Liaw's resignation, which caused an...
Charles Schwab reported strong Q2 2026 results with earnings per share of $1.62, exceeding estimates and marking a 42% increase year-over-year. The company achieved record quarterly revenue of $7.07 billion, driven by increased trading activity and h...
WesBanco, Inc. is set to release its Q2 2026 earnings with analysts expecting an EPS of $0.86 and revenue of $267.71 million. Despite a 75.7% increase in short interest, analyst sentiment remains positive, with upgrades from Weiss Ratings and Zacks R...
Law Offices of Howard G. Smith announced class action lawsuits against Futu Holdings, Hub Group, Insulet Corporation, and Photronics for allegedly making false or misleading statements during specific periods. The lawsuits claim these companies misre...
Traini, a Silicon Valley AI company specializing in pet emotional intelligence, has partnered with TECNO to integrate its pet emotion translation technology natively into TECNO smartphones. This allows users to understand their pets' emotions and nee...
